Baker Hughes heads into its July 21 earnings with a striking divergence: insiders have been selling heavily while options traders have shifted to their most bullish stance in months.
The insider activity is the standout this week. CEO Lorenzo Simonelli sold 181,411 shares on June 12 for roughly $11.5 million. CFO Ahmed Farhan Moghal followed three days later with a combined $1.46 million in sales. The Chief Accounting Officer also sold in early June. Net insider activity over the past 90 days totals a disposal of approximately $14.4 million in value — a consistent pattern of C-suite selling into what was, until recently, a stronger price. The stock has fallen 11% over the past month to $58.68, meaning those executives sold at materially better levels than where the stock trades now.
The options market is telling the opposite story. The put/call ratio has dropped to 0.71, nearly three standard deviations below its 20-day average of 0.78 — the lowest reading of the past year. That is an unusually call-heavy posture, suggesting options traders are leaning toward upside rather than seeking protection ahead of the Q2 print. The contrast with insider behaviour is hard to ignore: one group is hedging for gains, the other has been reducing exposure.
Short positioning is not the story here. At just under 3% of free float — roughly 29 million shares — short interest is modest, and borrow conditions are extremely loose. Availability runs above 4,300%, meaning there are more than 43 shares available to borrow for every one currently lent out. Cost to borrow has eased 16% over the week to 0.34%, near its lowest level in the dataset. Short sellers are not piling in despite the price weakness; the ORTEX short score of 35.7 sits in the middle of the range and has drifted slightly lower over the past two weeks.
The Street broadly likes the name but has trimmed ambitions. Most analysts lifted targets sharply after the April 27 Q1 beat — JP Morgan moved to $74, Citigroup to $80, BMO and Susquehanna also to $80. Then Citigroup's Scott Gruber cut his target back to $74 on June 3, even while holding his Buy rating, and Barclays downgraded to Equal-Weight while paradoxically raising its target to $74 from $62. The consensus mean target of $71.24 implies meaningful upside from current levels, though the stock has given back much of its post-Q1 rally. The price-to-earnings multiple has compressed by 3.5 points over 30 days to 23x, and price-to-book has shed 0.37 points to 2.68x. The EPS surprise factor score ranks in the 86th percentile — Baker Hughes has consistently delivered above expectations — but forward earnings momentum has deteriorated sharply, with the 90-day EPS momentum score ranking just 16th percentile. The dividend score, by contrast, sits at 99th percentile, pointing to strong income characteristics.
Closest peers have fared worse on the week. SLB dropped 14.6% and XPRO fell 15.7%. HAL and NOV both shed around 11%. BKR's 4.6% weekly decline looks relatively contained within that context, but the sector-wide pressure from softening upstream capex expectations is real and broad.
The July 21 earnings print therefore resolves the current tension between a call-heavy options market and a C-suite that has been reducing exposure — with the industrial and energy technology backlog conversion narrative the key datapoint to watch.
See the live data behind this article on ORTEX.
Open BKR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
